954
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Selol nanocapsules with a poly(methyl vinyl ether-co-maleic anhydride) shell conjugated to doxorubicin for combinatorial chemotherapy against murine breast adenocarcinoma in vivo

, , , , , , , , & show all
Pages 1046-1052 | Received 19 Apr 2018, Accepted 10 May 2018, Published online: 29 May 2018

Figures & data

Figure 1. Ex vivo fluorescence of Doxorubicin in organs collected from mice treated with free doxorubicin (DOX) or with nanocapsules containing selol and doxorubicin (NCS-DOX) at 2, 4 and 8 h post-administration. Each panel above shows the organs of one representative animal out of three studied for each time and treatment.

Figure 1. Ex vivo fluorescence of Doxorubicin in organs collected from mice treated with free doxorubicin (DOX) or with nanocapsules containing selol and doxorubicin (NCS-DOX) at 2, 4 and 8 h post-administration. Each panel above shows the organs of one representative animal out of three studied for each time and treatment.

Figure 2. Graphs presents the quantitative evaluation the DOX-specific fluorescence photon counts of DOX (free doxorubicin) and nanocapsules containing selol and doxorubicin (NCS-DOX), as photons per second per gram of tissue (p/s/g). Data are expressed as mean ± standard error of the mean for three animals.

Figure 2. Graphs presents the quantitative evaluation the DOX-specific fluorescence photon counts of DOX (free doxorubicin) and nanocapsules containing selol and doxorubicin (NCS-DOX), as photons per second per gram of tissue (p/s/g). Data are expressed as mean ± standard error of the mean for three animals.

Figure 3. Graphs represents the area under the curve of the data plotted in . Data are expressed as mean ± standard error of the mean for three animals.

Figure 3. Graphs represents the area under the curve of the data plotted in Figure 2. Data are expressed as mean ± standard error of the mean for three animals.

Figure 4. Graphs represents evolution of 4T1 tumours volume in mice treated with free doxorubicin (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS) and control group (vehicle only, which consisted of an aqueous solution of glucose 5% w:v). Treatments were performed at days 0, 3, 6 and 9 (arrows). Data are expressed as mean ± standard error of the mean. n = 6 mice per group. a=p < .05 versus all other treatments.

Figure 4. Graphs represents evolution of 4T1 tumours volume in mice treated with free doxorubicin (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS) and control group (vehicle only, which consisted of an aqueous solution of glucose 5% w:v). Treatments were performed at days 0, 3, 6 and 9 (arrows). Data are expressed as mean ± standard error of the mean. n = 6 mice per group. a=p < .05 versus all other treatments.

Figure 5. Graphs represent weight alteration in mice treated with free doxorubicin (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS), control group with and without tumour (vehicle only, which consisted of an aqueous solution of glucose 5% w:v).during the experiments. Data are expressed as mean ± standard error of the mean. n = 6 mice per group. a = p < .05 versus all other treatments.

Figure 5. Graphs represent weight alteration in mice treated with free doxorubicin (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS), control group with and without tumour (vehicle only, which consisted of an aqueous solution of glucose 5% w:v).during the experiments. Data are expressed as mean ± standard error of the mean. n = 6 mice per group. a = p < .05 versus all other treatments.

Figure 6. Graphs represent creatine kinase MB (CK-MB) activity in the serum of mice treated with doxorubicin alone (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS), and control mice, with and without tumour (vehicle only, which consisted of an aqueous solution of glucose 5% w:v). Data are expressed as mean ± standard error of the mean. a = p < .05 when compared to the other groups, except NCS.

Figure 6. Graphs represent creatine kinase MB (CK-MB) activity in the serum of mice treated with doxorubicin alone (DOX), nanocapsules containing selol and doxorubicin (NCS-DOX), nanocapsules of selol (NCS), and control mice, with and without tumour (vehicle only, which consisted of an aqueous solution of glucose 5% w:v). Data are expressed as mean ± standard error of the mean. a = p < .05 when compared to the other groups, except NCS.

Figure 7. Optical microscopy images of heart tissue of: (A) control tumour-bearing mice (received vehicle only, which consisted of an aqueous solution of glucose 5% w:v), (B) mice treated with nanocapsules of selol (NCS), (C) mice treated with doxorubicin alone (DOX), and (D) mice treated with nanocapsules containing selol and doxorubicin (NCS-DOX). Arrows in A indicate parallel muscle fibers and the perpendicular intercalated discs. The arrow in C indicates wavy muscle fibers. The circle in D shows inflammatory infiltrate. Classical staining with hematoxylin and eosin was used.

Figure 7. Optical microscopy images of heart tissue of: (A) control tumour-bearing mice (received vehicle only, which consisted of an aqueous solution of glucose 5% w:v), (B) mice treated with nanocapsules of selol (NCS), (C) mice treated with doxorubicin alone (DOX), and (D) mice treated with nanocapsules containing selol and doxorubicin (NCS-DOX). Arrows in A indicate parallel muscle fibers and the perpendicular intercalated discs. The arrow in C indicates wavy muscle fibers. The circle in D shows inflammatory infiltrate. Classical staining with hematoxylin and eosin was used.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.